P1‐252: CONCORDANCE OF QUANTITATIVE SUVR METHODS WITH VISUAL ASSESSMENT OF FLORBETAPIR PET SCREENING RESULTS
Gregory Klein(Roche (Switzerland)), Joyce Suhy(BioClinica (United States)), Jerome Barakos(Sutter Health), Jeff Sevigny(Ovid Therapeutics (United States)), Ping Chiao(Biogen (United States)), Mehul Sampat(Biogen (United States)), Joonmi Oh(Biogen (United States)), Derk D. Purcell(BioClinica (United States))
Cited by 2
Related Papers
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
|JAMA Neurology|2021|602
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
|Alzheimer s Research & Therapy|2017|568